EC
CERE

Elequin Capital’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Elequin Capital’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-99
Closed -$4.18K – 385
2024
Q1 		$4.18K Buy
99
+89
+890% +$3.74K ﹤0.01% 160
2023
Q4 		$424 Sell
10
-6
-38% -$172 ﹤0.01% 325
2023
Q3 		$349 Sell
16
-395
-96% -$9.88K ﹤0.01% 354
2023
Q2 		$13.1K Buy
+411
New +$12.6K 0.01% 274
2023
Q1 		– Sell
-922
Closed -$29.1K – 576
2022
Q4 		$29.1K Buy
+922
New +$26K 0.01% 356

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Elequin Capital's CERE Position: Q2 2024 in Review

Elequin Capital sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2024, closing a stake of 99 shares — an estimated $4.18K sold.

Elequin Capital first reported a position in CERE in Q4 2022 and held it in 5 quarters. The position peaked at $29.1K in Q4 2022. 231 funds tracked by Wall St. Rank hold CERE as of Q2 2024.

  • Elequin Capital reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Elequin Capital sold 99 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2024, an estimated $4.18K.
  • Elequin Capital first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022 and held it in 5 quarters.
  • Elequin Capital's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $29.1K in Q4 2022.
  • 231 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2024.

Based on Elequin Capital's 13F filing for Q2 2024, filed 12 Aug 2024.